160 related articles for article (PubMed ID: 23135345)
21. Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study.
Cohen A; Stein EM; Recker RR; Lappe JM; Dempster DW; Zhou H; Cremers S; McMahon DJ; Nickolas TL; Müller R; Zwahlen A; Young P; Stubby J; Shane E
J Clin Endocrinol Metab; 2013 May; 98(5):1971-81. PubMed ID: 23543660
[TBL] [Abstract][Full Text] [Related]
22. A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia.
Chen JF; Yang KH; Zhang ZL; Chang HC; Chen Y; Sowa H; Gürbüz S
Osteoporos Int; 2015 Jan; 26(1):11-28. PubMed ID: 25138261
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
24. An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide.
Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Nakamura T; Kono T; Sudo A
Osteoporos Int; 2014 Jan; 25(1):377-84. PubMed ID: 23812597
[TBL] [Abstract][Full Text] [Related]
25. Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women.
Shiraki M; Sugimoto T; Nakamura T
Osteoporos Int; 2013 Jan; 24(1):219-26. PubMed ID: 23093347
[TBL] [Abstract][Full Text] [Related]
26. Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis.
Gossiel F; Scott JR; Paggiosi MA; Naylor KE; McCloskey EV; Peel NFA; Walsh JS; Eastell R
J Clin Endocrinol Metab; 2018 Apr; 103(4):1302-1309. PubMed ID: 29365099
[TBL] [Abstract][Full Text] [Related]
27. Effects of teriparatide in Japanese and non-Japanese populations: bridging findings on pharmacokinetics and efficacy.
Tsujimoto M; Uenaka K; Iwata A; Higashiuchi Y; Sowa H
J Bone Miner Metab; 2012 May; 30(3):326-37. PubMed ID: 21938381
[TBL] [Abstract][Full Text] [Related]
28. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
Nakatoh S
J Bone Miner Metab; 2018 Mar; 36(2):221-228. PubMed ID: 28293779
[TBL] [Abstract][Full Text] [Related]
29. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
30. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
[TBL] [Abstract][Full Text] [Related]
31. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
Cosman F; Wermers RA; Recknor C; Mauck KF; Xie L; Glass EV; Krege JH
J Clin Endocrinol Metab; 2009 Oct; 94(10):3772-80. PubMed ID: 19584192
[TBL] [Abstract][Full Text] [Related]
32. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
33. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
34. Effect of Teriparatide on Bone Remodeling and Density in Premenopausal Idiopathic Osteoporosis: A Phase II Trial.
Cohen A; Shiau S; Nair N; Recker RR; Lappe JM; Dempster DW; Nickolas TL; Zhou H; Agarwal S; Kamanda-Kosseh M; Bucovsky M; Williams JM; McMahon DJ; Stubby J; Shane E
J Clin Endocrinol Metab; 2020 Oct; 105(10):e3540-56. PubMed ID: 32876328
[TBL] [Abstract][Full Text] [Related]
35. A multicenter, randomized, rater-blinded, parallel-group, phase 3 study to compare the efficacy, safety, and immunogenicity of biosimilar RGB-10 and reference once-daily teriparatide in patients with osteoporosis.
Hagino H; Narita R; Yokoyama Y; Watanabe M; Tomomitsu M
Osteoporos Int; 2019 Oct; 30(10):2027-2037. PubMed ID: 31243480
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Daily Teriparatide Treatment in Low Levels of Walking State Patients.
Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
Clin Drug Investig; 2017 Jun; 37(6):551-557. PubMed ID: 28247298
[TBL] [Abstract][Full Text] [Related]
37. Teriparatide Treatment in Patients With WNT1 or PLS3 Mutation-Related Early-Onset Osteoporosis: A Pilot Study.
Välimäki VV; Mäkitie O; Pereira R; Laine C; Wesseling-Perry K; Määttä J; Kirjavainen M; Viljakainen H; Välimäki MJ
J Clin Endocrinol Metab; 2017 Feb; 102(2):535-544. PubMed ID: 27732335
[TBL] [Abstract][Full Text] [Related]
38. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.
Sumida K; Ubara Y; Hoshino J; Mise K; Hayami N; Suwabe T; Kawada M; Imafuku A; Hiramatsu R; Hasegawa E; Yamanouchi M; Sawa N; Takaichi K
Osteoporos Int; 2016 Apr; 27(4):1441-1450. PubMed ID: 26525045
[TBL] [Abstract][Full Text] [Related]
39. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Burnett-Bowie SA; Zhu Y; Foley K; Lee H; Neer RM
J Clin Endocrinol Metab; 2014 May; 99(5):1694-700. PubMed ID: 24517156
[TBL] [Abstract][Full Text] [Related]
40. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]